微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2011, Vol. 3 ›› Issue (2): 130-.doi: 10.3969/j.issn.1674-5671.2011.02.09

• 临床研究 • 上一篇    下一篇

T淋巴母细胞淋巴瘤自体干细胞移植后的长期随访观察

卜 庆, 高 岩, 蔡清清, 林旭滨, 王潇潇, 孙晓菲, 甄子俊, 黄慧强   

  • 出版日期:2011-08-03 发布日期:2011-08-03

BU Qing, GAO Yan, CAI Qing-Qing, LIN Xu-Bin, WANG Xiao-Xiao, SUN Xiao-Fei, ZHEN Zi-Jun, HUANG Hui-Qiang   

  • Online:2011-08-03 Published:2011-08-03

PDF (PC)

746

赞

被引次数

11

摘要： 【摘要】目的 评价自体造血干细胞移植（autologous hematopoietic stem cell transplantation，AHSCT）治疗复发难治T淋巴母细胞淋巴瘤（TLBL）的临床疗效及安全性。方法 本文回顾性分析AHSCT治疗后长期随访的TLBL16例，预处理方案主要为BEAM和BEAC。结果15例患者可评价疗效，1例失访。中位随访37个月（12~132个月），中位无进展生存时间（PFS）34.5个月。预计中位总生存时间49月。1、3、5年总生存率分别为60%、53%、32%。初治患者一线治疗有效者，接受AHSCT者预计中位总生存时间为108个月，5年总生存率、无进展生存率分别为62%、63%；复发患者挽救治疗后接受AHSCT者，中位总生存时间为22.8个月，5年总生存率、无进展生存率分别为33%、22%。初始治疗未达CR/PR的难治患者，中位生存仅21个月，5年生存率和无进展生存率分别为20%和29%。结论AHSCT常规化疗治疗TLBL安全、有效，可提高复发难治的T淋巴母细胞淋巴瘤的远期生存，延长初治TLBL患者的无进展生存期，但复发率仍偏高，值得开展大规模临床试验进一步深入研究。

关键词: 【关键词】淋巴瘤, 自体造血干细胞移植, T淋巴母细胞性淋巴瘤

Abstract: 【Abstract】Objective To evaluate the clinical efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT) on treating patients with relapsed or refractory T-lymphoblastic lymphoma (TLBL). Methods 16 patients with TLBL were long-term followed-up and analyzed retrospectively. The major conditioning regimens were BEAM and BEAC. Results 15 patients were evaluable for efficacy and 1 patient lost in follow-up. The median progression-free survival (PFS) was 34.5 months. The expecting median overall survival time (OS) was 49 months. The rates of 1-，3-and 5-year OS were 60%，53% and 32% respectively. Among the newly diagnosed patients who were effectively first -line treated，the median OS was 108 months，the rates of 5-year OS and PFS were 62% and 63% respectively. Among the patients who had response after first-line treatment，the median OS was 22.8 months，the rates of 5-year OS and PFS were 33% and 22% respectively. Median OS for the heavily-treated or refractory patients was 21 months，the rates of 5-year OS and PFS were 20% and 29% respectivelyConclusionsAHSCT is effective and safe for TLBL after conventional chemotherapy. It can improve long-term survival and extend PFS on the initial treated patients，though the recurrent rate remains relatively high. Large-scale clinical trial is urgently warranted.

Key words: 【Key words】Lymphoma, Autologous hematopoietic stem cell transplantation, Lymphoblastic lymphoma